ANGO 250117 12.50C (ANGO250117C12500) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

ANGO250117C12500

Watchlist

0.09
+0.04+80.00%

15min DelayClose Jan 7 15:47 ET

0.15High0.09Low

Intraday

5D
Daily

News

AngioDynamics to Present at the J.P. Morgan Healthcare Conference
BusinesswireJan 6 09:26 ET
AngioDynamics to Host Virtual Event Showcasing the Innovative NanoKnife System
BusinesswireJan 6 09:25 ET
Earnings Week Ahead: TLRY, WBA, DAL, STZ, CALM and More
Seeking AlphaJan 5 08:02 ET
Earnings Preview: ANGO to Report Financial Results Pre-market on January 08
Moomoo NewsJan 2 20:00 ET
Press Release: AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event
Dow JonesDec 19, 2024 17:01 ET
AngioDynamics, Inc. (NASDAQ:ANGO) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
Simply Wall StDec 13, 2024 05:36 ET

Comments

Trytosaveabit

Dec 9, 2024 12:42

$AngioDynamics (ANGO.US)$ Not to shabby! Lets try to push for a NHOD? Hehehe

Trytosaveabit

Dec 9, 2024 05:04

News

$AngioDynamics (ANGO.US)$ The FDA Has Granted 510(k) Clearance For AngioDynamics' Nanoknife System For Prostate Tissue Ablation
Benzinga· 1 min ago

Jaguar8

Dec 9, 2024 05:01

NEWS

$AngioDynamics (ANGO.US)$
AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for the NanoKnife System for prostate tissue ablation.
Th...

Trytosaveabit

Oct 23, 2024 07:15

Update

$AngioDynamics (ANGO.US)$ Benzinga· 1 min ago
AngioDynamics, University College London Hospital Launch International Multi-Center Study On Long Term Effects Of Treatment With NanoKnife System

Jaguar8

Sep 19, 2024 15:48

NEWS

$AngioDynamics (ANGO.US)$
AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes
AngioDynamics, Inc. (NASDAQ: ANGO) has launched the RECOVER-AV clinical trial to evaluate the AlphaVac F18⁸⁵ System for treating acute, intermediate-risk pulmonary embolism (PE) in the European market.
This multi-center, multi-national study follows the successful APEX-AV trial in the US, which showed significant impr...